JAMPRO
30.4.2021 15:34:12 CEST | Business Wire | Press release
Global outsourcing powerhouse, ibex , is increasing the diversity of jobs within Jamaica’s global digital services industry through an expansion of its current workforce of two thousand employees. The company provides customer support in sectors that include retail, finance, healthcare, and telecommunications, and it now offers a broad spectrum of business services from its Jamaican service centres.
With a client list heavily concentrated in the US, Europe, and Asia, ibex identified Jamaica as the perfect place for rapid expansion due to the island’s location and high-quality talent.
“ibex has experienced incredible growth in Jamaica - in the last three years we’ve grown 397%,” Country Director Jaime Vergara revealed. “We have gone from ranking as the 17th outsourcing company on the island for number of employees to number one, and ibex has been recognized for not only our growth, but for our performance, by organisations like Frost & Sullivan, a leading industry analyst group, and as Nexus Nearshore BPO of the Year in 2019 by Nearshore Americas.”
The high-calibre staff ibex has attracted has cleared the way for it to bring more business to Jamaica’s outsourcing industry and it now offers Knowledge Process Outsourcing (KPO) services from the island’s service centres. KPO is the outsourcing of information-related business activities such as accounting outsourcing, human resources (HR) outsourcing, digital marketing and management consultancy. Legal, medical and other healthcare analyses are additional examples of KPO.
As the world further relies on BPO and KPO during the COVID-19 pandemic, it is predicted that more business services will be digitised during and after the crisis. This and other factors will increase the demand for outsourcing, creating the environment for ibex to safely execute its growth plans both in Jamaica, and globally.
“We plan on prolonging our unprecedented growth and we hope to reach 10,000 employees in Jamaica over the next few years,” Vergara disclosed.
With the specialised skills needed for KPO, Vergara said Jamaica was the perfect location for ibex to offer these services. “Jamaica offers a talented and educated labour pool which is what has made us attractive to our clients, particularly in the financial services sector,” he said. “Through programs like the GSSP (Global Services Sector Project), the employees we hire are on a career path and are looking for companies to join where they can be successful. They are eager to work with their customers in their specialised area.”
Vergara also expressed appreciation for private and public sector partnerships including entities such as the Office of the Prime Minister, the Jamaica Special Economic Zone Authority (JSEZA) and the Jamaica Promotions Corporation (JAMPRO) among others.
JAMPRO, for example, has supported ibex as an investment facilitation partner, beginning with the launch of the first service centre in Portmore. The company now has five service centres across Jamaica.
ibex believes that its advancement into KPO has led to increased customer confidence, displaying the company’s adaptation to the needs of today’s clients. The company looks forward to more expansion in Jamaica.
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005093/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom